Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-898 first-in-human study in advanced solid tumors
NL-OMON61686Phase 2Not yet recruiting
- Sponsor
- Antares Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ATX-898 in Nonhematologic neoplasms and breast cancer (6 arms), sponsored by Antares Therapeutics. Primary endpoints: Dose-limiting toxicities and safety, Clinical safety assessments and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ATX-898
03
Conditions
Nonhematologic neoplasmsbreast cancer
Beyond the preview
Go deeper on NL-OMON61686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61686.